INSTI switching linked to higher metabolic risk in people with HIV
Switching HIV meds raises diabetes risk but not heart attack danger
A global cohort study found that switching to integrase inhibitors increased risks for obesity, diabetes, and hypertension, but not MACE, ov…
Switching HIV medication to a newer class may raise the risk of diabetes and weight gain, but it does not appear to increase the risk of hea…
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
Integrase Inhibitors Show Lower Event Rates Than Boosted Protease Inhibitors in Advanced HIV
This trial compared an integrase inhibitor regimen with a boosted protease inhibitor regimen in therapy-naive adults with advanced HIV disea…
A trial of 447 therapy-naive adults with advanced HIV found fewer drug-related side effects with an integrase inhibitor regimen compared to …